TD Cowen downgraded IO Biotech (IOBT) to Hold from Buy without a price target after the FDA recommended the company not file an application for Cylembio plus pembrolizumab in melanoma. IO is reducing its workforce by 50% but the company’s cash “is tight” at $38M into Q1 of 2026, the analyst tells investors in a research note. TD cites IO’s lack of late-stage catalysts for the downgrade.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOBT:
- IO Biotech downgraded to Neutral from Buy at H.C. Wainwright
- H.C. Wainwright downgrades IO Biotech after FDA recommends another Phase 3 trial
- FDA Recommends Against IO Biotech’s Cylembio Application
- IO Biotech says FDA reccomends not submitting BLA based on IOB-013 trial data
- IO Biotech implements plan to conserve capital, 50% reduction in full-time staff